age-related macular degeneration
Conditions
Interventions
Patients receive three monthly intravitreal injections of ranibiumab (0.5mg) and followed up monthly for 12 months. Repeat injections were given to patients who showed insufficient effects of treatmen
Sponsors
Kyoto University Graduate School of Medicine, Department of Ophthalmology and Visual Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Treatment naive active angiographically subfoveal choroidal neovascularization associated with age-ralated macular degeneration with best corrected visual acuity of 32/40 to 20/400
Exclusion criteria
Exclusion criteria: Previous treatment with photocoagulation, surgery, photodynamic therapy, Transpupillary thermotherapy, radiation Subfoveal fibrosis or atrophy History of vitrectomy Intraocular surgery within 2 months CNV in either eye due to other causes, such as ocular histo-plasmosis, trauma, or pathological myopia Aphakia or absence of the posterior capsule in the study eye unless it resulted from yttrium aluminum garnet (YAG) posterior capsulotomy in association with prior posterior chamber intraocular lens implantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| visual acuity change at 12 months after the first treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| disappearance of retinal exudative change at 3 months, visual acuity change at 3 months, interval for additional treatment, and number of treatment during 12 months | — |
Countries
Japan
Contacts
Public ContactKenji Yamashiro
Kyoto University Graduate School of Medicine Department of Ophthalmology and Visual Sciences
Outcome results
None listed